Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia : An observational study
Copyright © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved..
OBJECTIVE: To estimate the effect of tocilizumab or glucocorticoids in preventing death and intubation in patients hospitalized with SARS-CoV-2 pneumonia.
METHODS: This was a retrospective cohort study enrolling all consecutive patients hospitalized at Reggio Emilia AUSL between February the 11th and April 14th 2020 for severe COVID-19 and treated with tocilizumab or glucocorticoids (at least 80 mg/day of methylprednisolone or equivalent for at least 3 days). The primary outcome was death within 30 days from the start of the considered therapies. The secondary outcome was a composite outcome of death and/or intubation. All patients have been followed-up until May 19th 2020, with a follow-up of at least 30 days for every patient. To reduce confounding due to potential non-comparability of the two groups, those receiving tocilizumab and those receiving glucocorticoids, a propensity score was calculated as the inverse probability weighting of receiving treatment conditional on the baseline covariates.
RESULTS AND CONCLUSION: Therapy with tocilizumab alone was associated with a reduction of deaths (OR 0.49, 95% CI 0.21-1.17) and of the composite outcome death/intubation (OR 0.35, 95% CI 0.13-0.90) compared to glucocorticoids alone. Nevertheless, this result should be cautiously interpreted due to a potential prescription bias.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases - 26(2022), 1 vom: 15. Jan., Seite 101702 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dolci, Giovanni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 15.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bjid.2021.101702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334993962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334993962 | ||
| 003 | DE-627 | ||
| 005 | 20231225224855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bjid.2021.101702 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM334993962 | ||
| 035 | |a (NLM)34963560 | ||
| 035 | |a (PII)S1413-8670(21)00171-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dolci, Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia |b An observational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a OBJECTIVE: To estimate the effect of tocilizumab or glucocorticoids in preventing death and intubation in patients hospitalized with SARS-CoV-2 pneumonia | ||
| 520 | |a METHODS: This was a retrospective cohort study enrolling all consecutive patients hospitalized at Reggio Emilia AUSL between February the 11th and April 14th 2020 for severe COVID-19 and treated with tocilizumab or glucocorticoids (at least 80 mg/day of methylprednisolone or equivalent for at least 3 days). The primary outcome was death within 30 days from the start of the considered therapies. The secondary outcome was a composite outcome of death and/or intubation. All patients have been followed-up until May 19th 2020, with a follow-up of at least 30 days for every patient. To reduce confounding due to potential non-comparability of the two groups, those receiving tocilizumab and those receiving glucocorticoids, a propensity score was calculated as the inverse probability weighting of receiving treatment conditional on the baseline covariates | ||
| 520 | |a RESULTS AND CONCLUSION: Therapy with tocilizumab alone was associated with a reduction of deaths (OR 0.49, 95% CI 0.21-1.17) and of the composite outcome death/intubation (OR 0.35, 95% CI 0.13-0.90) compared to glucocorticoids alone. Nevertheless, this result should be cautiously interpreted due to a potential prescription bias | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Besutti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Corsini, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Sampaolesi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Iotti, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Adalgisa |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Mancuso, Pamela |e verfasserin |4 aut | |
| 700 | 0 | |a Reggio Emilia COVID-19 Working Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases |d 1997 |g 26(2022), 1 vom: 15. Jan., Seite 101702 |w (DE-627)NLM09750825X |x 1678-4391 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:101702 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bjid.2021.101702 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 1 |b 15 |c 01 |h 101702 | ||